Adoptive T-cell therapy for fungal infections in haematology patients
The 1-year mortality associated with IFDs is ~75% in HSCT patients with invasive aspergillosis, ~65% in patients with invasive candidiasis, ~70% in patients with invasive zygomycoses and over 90% in patients with invasive fusariosis. Various risk ...
Nature.com - Fri, 14 Aug 2015 00:21

Cidara Therapeutics to Present Data from Antifungal Drug Development Programs ...
The company will also present one poster summarizing results from studies of its Cloudbreak™ targeted immunotherapy platform. In total, three oral presentations and 14 poster presentations regarding CD101 IV, CD101 Topical and Cloudbreak™ have been ...
MarketWatch - Mon, 10 Aug 2015 03:52

Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and ...
QIDP and Fast Track designations have been granted for the use of MAT2203 in the treatment of invasive candidiasis, a condition with increasing rates of drug resistance to established anti-fungal products. ... In a clinical Phase 1a single-dose, double ...
CNNMoney - Tue, 18 Aug 2015 03:52

SCYNEXIS, Inc. Reports Second Quarter 2015 Financial Results
(vulvovaginal candidiasis, VVC). VVC is a highly prevalent condition with limited therapeutic options for infections caused by azole-resistant Candida spp. We plan to commence a Phase 2 study of the oral formulation of SCY-078 during the fourth quarter ...
Nasdaq - Wed, 19 Aug 2015 14:56



Cannabis On A High, PTN Jumps On Sprout News, TNXP At Ease, Watch APHB On Friday
Lannett Company Inc. (LCI) has received FDA approval for its Abbreviated New Drug Application for Aripiprazole Oral Solution 1 mg/mL, the generic version of the antidepressant drug ABILIFY, manufactured by Otsuka/Bristol-Myers. Lannett's generic ...
RTT News - Wed, 19 Aug 2015 00:07

Beware of skin complications of newer antidiabetic agents
They are oral agents. Their most common cutaneous side effect is candidiasis, occurring in about 10% of patients. Women and uncircumcized men are at greatest risk. Fortunately, most cases are mild, episodic, and successfully treated with topical or ...
Clinical Endocrinology News Digital Network - Tue, 11 Aug 2015 15:51



Causes And Treatment For Oral Thrush In Babies
Candidiasis is a yeast infection of the mucus membrane lining the mouth and tongue. The alternative name for candidiasis is oral thrush. Causes, incidence, and risk factors. The body normally hosts a variety of germs, including bacteria and fungi. Some ...
BoldSky - Wed, 17 Jun 2015 05:06

DARA BioSciences Nabs US Rights to Oral Thrush Drug
Raleigh, NC-based DARA plans to announce today that it has acquired U.S. rights to miconozole (Oravig), an antifungal drug approved to treat oral candidiasis, commonly called oral thrush. DARA is disclosing no financial terms for the agreement to ...
Xconomy - Tue, 10 Mar 2015 04:00

DARA BioSciences (DARA) Acquires North American Rights to Oravig
StreetInsider.com - Tue, 10 Mar 2015 04:03


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014